Last reviewed · How we verify
Moisturizer
At a glance
| Generic name | Moisturizer |
|---|---|
| Sponsor | University of Florence |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC) (PHASE3)
- Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib (PHASE2)
- A 16-week Clinical Study Investigating a Dark Spot Corrector Serum in Women With Moderate Discrete Hyperpigmentation (NA)
- Postpartum Vaginal Estrogen for Breastfeeding Patients (PHASE4)
- Changes in Scalp Condition After Using a Moisturizer: a Prospective Clinical Trial Using Artificial Intelligence (NA)
- Skin Barrier Function and Inflammation in Aging: The BIA Study (PHASE4)
- Endocare Repair Efficacy Skincare Products in the Use of Post-laser Treatment (NA)
- Seal, Stopping Eczema and Allergy Study (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Moisturizer CI brief — competitive landscape report
- Moisturizer updates RSS · CI watch RSS
- University of Florence portfolio CI